Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug
(By Judith Graham for Kaiser Health News) As physicians and health policy experts debate the merits of Aduhelm, the first
Read More
Alzheimer’s/Dementia
Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
(By Judith Graham for Kaiser Health News) If you could invest $56 billion each year in improving health care for
Read MoreMedicare could limit who gets new Alzheimer’s drug
(By Lauren Jensik for Becker’s Hospital Review) Medicare members could face barriers to accessing Biogen’s new Alzheimer’s drug, Aduhelm, due to
Read MoreWill Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read MorePoint32Health challenges Aduhelm, threatens coverage for 1.1M members
(By Nick Moran for Becker’s Hospital Review) Point32Health may not cover Biogen’s new Alzheimer’s treatment, Aduhelm, for its commercial members unless
Read MoreA crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
(By Megan Molteni for STAT) For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s
Read MoreQ&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
(By Andrew Joseph for STAT) Harry Johns is ready to stop talking about whether or not the Food and Drug
Read More‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients
(By Elizabeth Cooney for STAT) Their phones are ringing off the hook and their email inboxes are filling up with
Read MoreFDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published June 10, 2021) The question of what would happen when
Read MoreThe FDA Has Approved A New Alzheimer’s Drug — Here’s Why That’s Controversial
(By Scott Hensley, Jon Hamilton, and Laurel Wamsley for NPR) The Food and Drug Administration approved the drug aducanumab to
Read More